Novartis' $12 Billion Acquisition of Avidity Yields Success with Phase 1/2 Victory in Muscular Dystrophy Trials

Novartis’ $12 Billion Acquisition of Avidity Yields Success with Phase 1/2 Victory in Muscular Dystrophy Trials